Investigational drug · Phase 2
VG712
Also called: A-dmDT390-bisFv fusion protein, UCHT1
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mycosis Fungoides.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VG712"
First trial start
2026
Jul 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VG712", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mycosis Fungoides
Largest trials
Live from ClinicalTrials.gov: studies naming "VG712" as an intervention, largest first.
- A Study of VG712 in Patients With Mycosis FungoidesPivotal-lookingNot yet recruiting
Virogen Biotechnology Inc.Industry
NCT07529405 · 386 participants (planned) · Start Jul 30, 2026 · Primary completion Dec 30, 2030
Drug: VG712; Mogamulizumab · For: Mycosis Fungoides
Sites: Tampa, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Proteolytic Activation of T Cell Engagers And Bispecific Proteins Using Modular Coiled-Coil Peptides.
Mondal B, Haikal YA, Kwong GA, et al. · ACS Chem Biol 2026
- Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.
Prakash N, Hörner S, Hagelstein I, et al. · J Transl Med 2026
- Translational strategy to support the first-in-human study of a TCR-like T cell bispecific with an in vitro-based safety approach.
Augustin A, Avignon B, Boetsch C, et al. · Front Immunol 2026
- IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia.
Fischer C, Chen SS, Nimmerfroh J, et al. · Haematologica 2026
- A novel SadP-scFv UCHT1 lectibody activates T cells and mediates lysis of Burkitt's lymphoma cells.
Tomisch J, Gräber J, Makshakova ON, et al. · RSC Chem Biol 2026
- Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers.
Lee H, Lee Y, Chung J · Semin Hematol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.